Navigation Links
arGEN-X Receives Two Preclinical Milestone Payments Under Collaboration With Shire
Date:1/13/2014

BREDA, The Netherlands and GHENT, Belgium, January 13, 2014 /PRNewswire/ --

Enters into pilot research agreement with Boehringer Ingelheim

arGEN-X, a clinical stage human therapeutic antibody company, announces the attainment of two important success milestones in its SIMPLE Antibody™ research and product development collaboration with Shire. The milestones, which trigger undisclosed payments from Shire, relate to demonstration of in vivo proof of concept for one of the ongoing antibody discovery programs.

Initiated in February 2012, the collaboration is focused on creating human therapeutic antibodies against complex targets implicated in severe, rare genetic diseases. Shire has an option to license the most promising antibody leads for further development and commercialization worldwide, in return for fee, milestone and royalty payments.

"Yet again the functional diversity of SIMPLE Antibodies™ has enabled our scientists to set a precedent in validating highly complex targets both in vitro and in vivo and identifying antibody leads with exciting therapeutic potential," said Hans de Haard, PhD, Chief Scientific Officer of arGEN-X. "We value our collaboration with Shire very highly and continue to make excellent progress through the outstanding joint efforts of our teams."

"We are very impressed by the productivity and consistent success of our therapeutic antibody collaboration with arGEN-X," said  Albert Seymour, Head of Discovery Biology and Translational Research at Shire.

arGEN-X today also announced the initiation of a new pilot research agreement with Boehringer Ingelheim. No further details are being disclosed at this stage.

About arGEN-X

arGEN-X is a clinical stage human therapeutic antibody company that is rapidly developing a product pipeline using its unique suite of antibody technologies. arGEN-X is creating first and best in class antibody therapeutics with highly differentiated target product profiles. Its therapeutic antibody programs, focused on cancer and autoimmune indications, are designed to deliver tangible benefits to patients with these diseases.

http://www.argen-x.com

 


'/>"/>
SOURCE arGEN-X
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. arGEN-X Appoints Dr. David L. Lacey to its Supervisory Board
2. arGEN-X Announces Preclinical Development of ARGX-112 for Dermatology
3. arGEN-X Identifies Potent Antibody Antagonists against Complex Chronic Pain Target Nav1.7
4. arGEN-X Initiates Phase IbStudy of ARGX-111 in Cancer
5. arGEN-X raises EUR 5 Million from PMV in Extension of EUR 32.5 Million Series B
6. arGEN-X Starts Phase Ib Expansion Cohorts With ARGX-110, a Novel Anti-CD70 Antibody, in Cancer Patients
7. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
8. Leica Biosystems Receives FDA Approval for the Fully Automated Bond Oracle™ HER2 IHC System on the Leica BOND-MAX
9. Nephros Receives 510(k) Clearance for Hemodiafiltration System
10. ProUroCare Medical Receives FDA Clearance for ProUroScan Elasticity Imaging System
11. BONESUPPORT Receives Red Herring 2012 Top 100 Europe Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)...  Diplomat Specialty Infusion Group, a brand of Diplomat Pharmacy, Inc. ... Iowa location. The Iowa ... an ISO 7 cleanroom—the standard needed to compound intravenous (IV) nutrition ... of pollutants. "Our new cleanroom ... serve our Iowa patients," said Phil ...
(Date:6/5/2017)... OMAHA, Neb. , June 5, 2017 /PRNewswire/ ... chair in the United States ... chair that helps a fallen person up to an ... is easily assembled and operated by one assistant and ... hand. It is simple enough that a child can ...
(Date:6/2/2017)... 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a leading medical technology ... findings demonstrating positive biochemical outcomes related to more frequent ... data will be presented at the ERA-EDTA Congress being ... . The research was conducted ... in Europe (KIHDNEy) Cohort ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... 23, 2017 , ... Ulster University, Magee Campus in Northern Ireland is hosting ... pm to present to graduate students exciting new and innovative hope research based on ... by The Health Improvement Service of the Western Health & Social Care Trust (WHSCT) ...
(Date:6/23/2017)... ... 23, 2017 , ... Moore Insurance, an eastern Texas firm ... asset protection and financial planning services, is teaming up with the For A ... children with cancer and other chronic diseases. , The For A Day Foundation ...
(Date:6/22/2017)... ... June 22, 2017 , ... Children’s National Health System ... (AHA) to launch a Rheumatic Heart Disease Center, with the goal of developing ... heart disease (RHD) in high-risk, financially disadvantaged countries and low-income communities across the ...
(Date:6/22/2017)... ... June 23, 2017 , ... Rise Against Hunger and ... 21, 2017, at the Emeryville Center of Community Life. More than 374 Clif ... , Rise Against Hunger (formerly Stop Hunger Now) meal packaging events are a ...
(Date:6/20/2017)... ... June 20, 2017 , ... Caduceus International ... pleased to announce a new online course entitled Personal & Community Health ... and evidence-based strategies for achieving optimal well-being and teaches students how to apply ...
Breaking Medicine News(10 mins):